Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma

15 Nov 2017

Abstract excerpt

Long noncoding RNA (lncRNA) has been identified to serve a critical role in the development of various types of cancer. Cancer susceptibility candidate 2 (CASC2) is a cancer‑associated lncRNA. However, whether CASC2 regulates osteosarcoma progression remains unclear. Reverse transcription‑quantitative polymerase chain reaction, western blot, invasion and migration assays were used to evaluate the role of CASC2 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to Mycobacterium research and diagnosis
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29257211
DOI: 10.3892/mmr.2017.8080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcomaPMID 29257211Read ↗

Overexpression of long non-coding RNA cancer susceptibility 2 inhibits cell invasion and angiogenesis in gastric cancerSemantic proximity Read ↗

Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/β-catenin signaling pathwaySemantic proximity Read ↗

Cancer Susceptibility Candidate 9 (CASC9): A Novel Targetable Long Noncoding RNA in Cancer TreatmentSemantic proximity Read ↗

Upregulation of lncRNA CASC2 Suppresses Cell Proliferation and Metastasis of Breast Cancer via Inactivation of the TGF-β Signaling PathwaySemantic proximity Read ↗

LncRNA CCAT2 promoted osteosarcoma cell proliferation and invasionSemantic proximity Read ↗

Long noncoding RNA CASC2 alleviates the growth, migration and invasion of oral squamous cell carcinoma via downregulating CDK1.Semantic proximity Read ↗

LncRNA CCAT2 enhances cell proliferation via GSK3β/β-catenin signaling pathway in human osteosarcoma.Semantic proximity Read ↗

LncRNA CASC11 promotes the cervical cancer progression by activating Wnt/beta-catenin signaling pathwaySemantic proximity Read ↗

Long non-coding RNA CASC2 upregulates PTEN to suppress pancreatic carcinoma cell metastasis by downregulating miR-21Semantic proximity Read ↗

Long non-coding RNA CCAT2 promotes cholangiocarcinoma cells migration and invasion by induction of epithelial-to-mesenchymal transition.Semantic proximity Read ↗

Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance.Semantic proximity Read ↗

LncRNA CASC9 promotes tumorigenesis by affecting EMT and predicts poor prognosis in esophageal squamous cell cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.